Catheter Precision Inc.
$ 0.99
3.12%
03 Jun - close price
- Market Cap 2,584,800 USD
- Current Price $ 0.99
- High / Low $ 0.99 / 0.92
- Stock P/E N/A
- Book Value 2.62
- EPS -10.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -1.80 %
- 52 Week High 15.77
- 52 Week Low 0.75
About
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-18 | 2025-11-13 | 2025-08-11 | 2025-05-14 | 2025-03-31 | 2024-11-13 | 2024-08-14 | 2024-05-06 | 2024-03-28 | 2023-12-15 | 2023-09-28 | 2023-06-02 |
| Reported EPS | -1.3874 | -1.7 | -5.93 | -0.3585 | -1.3475 | -38.19 | -105.83 | -68.4 | -2.8 | -0.28 | -11.5 | -24.65 |
| Estimated EPS | None | 0.08 | 0.02 | 0.05 | -0.2 | -3.42 | -4.94 | -7.98 | -2.3 | -0.23 | -3.02 | -0.34 |
| Surprise | 0 | -1.78 | -5.95 | -0.4085 | -1.1475 | -34.77 | -100.89 | -60.42 | -0.5 | -0.05 | -8.48 | -24.31 |
| Surprise Percentage | None% | -2225% | -29750% | -817% | -573.75% | -1016.6667% | -2042.3077% | -757.1429% | -21.7391% | -21.7391% | -280.7947% | -7150% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTAK
2026-05-23 03:40:06
This page provides a stock chart for CATHETER PRECISION INC (NYSEARCA:VTAK), displaying its current stock price and recent price movements. It also offers various links for trading tools, market data, educational resources, and different views of the stock chart (daily, weekly, monthly, candles, bar, line). The article indicates the stock's performance as of May 22, 2026.
2026-05-21 12:41:23
Catheter Precision, Inc. announced its financial results for the first quarter of 2026, reporting a net loss of $1.7 million, a significant improvement from the $4.0 million net loss in Q1 2025. The company saw a 200% year-over-year revenue increase to $432,000, driven by strong growth in its medical device segment and rapid scaling of its newly acquired Flyte platform. Its electrophysiology platform expanded globally, gaining traction with new customer acquisition in the US and Europe, and new clinical publications validated its LockeT and VIVO technologies.
2026-05-18 20:39:55
Catheter Precision (NYSE: VTAK) announced a 200% year-over-year revenue increase in Q1 2026, reaching $432,000, primarily driven by its medical device segment and the newly acquired Flyte aviation platform. The company also significantly reduced its net loss from $4.0 million to $1.7 million. Flyte rapidly scaled its fleet and achieved a $200,000 monthly revenue run rate within 22 days post-acquisition, positioning Catheter Precision as a dual-engine growth platform in healthcare and regional air mobility.
2026-05-18 13:41:23
Catheter Precision experienced revenue growth in Q1 2026 due to both its cardiac and new private aviation segments, partly driven by the FLYTE acquisition. However, the company reported a $1.7 million net loss and faces significant liquidity and dilution risks. These financial challenges raise concerns about the company's going concern status despite increased revenue.
2026-05-18 12:25:22
Catheter Precision (VTAK) has announced a brief delay in its Form 10-Q filing for Q1 2026, which is attributed to the complex accounting required for its recent acquisition of Fly Flyte, Inc. and Ponderosa Air, LLC. The company expects to file within the SEC's five-day extension and does not anticipate any significant changes to its quarterly results. Spark, TipRanks' AI Analyst, rates VTAK as Neutral due to weak financial performance and bearish technical trends, despite supportive corporate financing actions.
2026-05-18 12:00:22
Catheter Precision (NYSE:VTAK) reported a 200% year-over-year revenue increase in Q1 2026, reaching $432,000, largely driven by its medical device business and the recent acquisition of the Flyte aviation platform. The company also significantly reduced its net loss to $1.7 million from $4.0 million in the previous year. This growth is attributed to global expansion of its medical device segment and Flyte's rapid scaling, which achieved a $200,000 monthly revenue run rate within 22 days post-acquisition.
